/ Cancer Resources
Cancer Blog and Resources
Articles
Safety outcomes with first-line treatment of Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) is comparable...
Understanding HER2 as a tumor-agnostic biomarker in cancer care and what it means for treatment...
8 health insurance benefits to ask for after breast cancer A breast cancer diagnosis doesn’t...
CDK 4/6 inhibitor side effects, treatment length, and more Dr. Pooja Advani is a breast...
Enhertu (fam-trastuzumab deruxtecan-nxki or T-DXd) has shown promising results in slowing down or stopping the...
The American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30...
A recent study is aiming to understand and classify the HER2 protein levels in breast...
One of the most important first steps after receiving a breast cancer diagnosis is understanding...
